Lymphoma, Positron-Emission Tomography, Tumor, Solid
Conditions
Keywords
Lymphoma, Positron-Emission Tomography, FAPI
Brief summary
To evaluate the normal physiological distribution of positron nuclide labeled NOTA-F API in human body and its detection efficiency for lymphoma
Detailed description
Subjects first undergo an 18F-FDG test, followed by 68Ga-NOTA-FAPI04 or 18F-NOTA-FAPI04 test in groups.Investigate the standardized uptake value(SUV) of 68Ga/ 18F-NOTA-FAPI04 for the target lesion, the ratio of the standardized uptake value(SUVR) of 68Ga/ 18F-NOTA-FAPI04 for the target lesion within each time window to that of the normal corresponding tissue.
Interventions
DIAGNOSTIC_TEST18F-FDG and 68Ga-NOTA-FAPI04 PET/CT
Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
DIAGNOSTIC_TEST18F-FDG and 18F-NOTA-FAPI04 PET/CT
Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
Sponsors
Peking University Cancer Hospital & Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* ECOG score 0 or 1 * subjects with lymphoma or suspected tumor subjects who have recently (within 2 months) planned to receive pathological biopsy or tumor surgery * expected survival ≥12 weeks * blood routine, liver and kidney function meet the following criteria: blood routine: WBC≥4.0×109L or neutrophils ≥1.5×109L, PLT≥100×109/L, Hb≥90g/L;PT and APTT ULN 1.5 or less;Liver and kidney function: t-bil ≤1.5×ULT(upper limit of normal value), ALT/AST≤2.5ULN or ≤5×ULT(subjects with liver metastasis), ALP≤2.5ULN(ALP≤ 4.5ULN if there is bone metastasis or liver metastasis);BUN 1.5 x or less ULT, SCr 1.5 x or less ULT * at least one measurable target lesion according to RECIST1.1 * women must use effective contraception during the study period and for 6 months after the end of the study (effective contraception means sterilization, hormone devices, condoms, contraceptives/pills, abstinence or vasectomy by a partner, etc.);Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period * able to understand and sign the informed consent voluntarily, with good compliance.
Exclusion criteria
* severe abnormalities of liver and kidney function; * women preparing for pregnancy, pregnancy and lactation; * cannot lie supine for half an hour; * refuse to join the clinical researcher; * suffering from claustrophobia or other mental illness; * conditions that other researchers considered inappropriate for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SUV | 60 days | Standardized uptake value of 68Ga/ 18f-nota-fapi04 for target lesion of subject or suspected tumor in each time point window (SUV) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SUVR | 60 days | the ratio of the standardized uptake value(SUVR) of 68Ga/ 18f-nota-fapi04 for the target lesion or suspected tumor lesion within each time window to that of the normal tissue corresponding to the tumor lesion or suspected tumor lesion to the standardized uptake value of 68Ga/ 18f-nota-fapi04 |
Countries
China
Contacts
Primary ContactXuejuan Wang, MD
Outcome results
None listed